Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
247.76
-8.76 (-3.41%)
Aug 11, 2026, 12:05 PM EDT - Market open
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuroscience | 2.97B | 2.96B | 2.88B | 2.82B | 2.75B | 2.72B | 2.70B | 2.66B | |||||||||||||||
| Neuroscience Growth | 8.05% | 8.81% | 6.68% | 6.01% | 4.40% | 3.25% | -0.35% | -3.68% | |||||||||||||||
| Oncology | 1.32B | 1.23B | 1.13B | 1.08B | 1.08B | 1.08B | 1.11B | 1.09B | |||||||||||||||
| Oncology Growth | 22.29% | 13.79% | 1.56% | -0.93% | 1.04% | 3.77% | 9.47% | 13.26% |
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rylaze Enrylaze | 411.23M | 412.39M | 402.92M | 396.25M | 395.16M | 402.33M | 410.85M | 411.11M | |||||||||||||||
| Rylaze Enrylaze Growth | 4.07% | 2.50% | -1.93% | -3.61% | -5.28% | -2.12% | 4.22% | 10.08% | |||||||||||||||
| Zepzelca | 376.54M | 345.28M | 307.31M | 295.20M | 301.75M | 308.25M | 320.32M | 316.00M | |||||||||||||||
| Zepzelca Growth | 24.79% | 12.01% | -4.06% | -6.58% | -2.08% | 3.63% | 10.63% | 9.92% | |||||||||||||||
| Defitellio Defibtrotide | 220.02M | 206.13M | 199.39M | 198.17M | 212.24M | 209.55M | 216.57M | 210.00M | |||||||||||||||
| Defitellio Defibtrotide Growth | 3.67% | -1.63% | -7.93% | -5.63% | 10.59% | 8.80% | 17.70% | 20.99% | |||||||||||||||
| Modeyso | 137.17M | 88.97M | 47.57M | 11.03M | - | - | - | - | |||||||||||||||
| Vyxeos | 130.31M | 143.77M | 146.71M | 165.23M | 161.96M | 160.12M | 162.60M | 156.26M | |||||||||||||||
| Vyxeos Growth | -19.54% | -10.21% | -9.77% | 5.74% | 6.71% | 12.11% | 10.24% | 19.42% |
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xywav | 1.78B | 1.72B | 1.66B | 1.59B | 1.55B | 1.50B | 1.47B | 1.41B | |||||||||||||||
| Xywav Growth | 14.63% | 14.49% | 12.48% | 13.00% | 14.58% | 14.67% | 15.73% | 15.77% | |||||||||||||||
| Epidiolex | 1.13B | 1.09B | 1.06B | 1.05B | 996.07M | 991.44M | 972.42M | 938.00M | |||||||||||||||
| Epidiolex Growth | 13.61% | 10.07% | 8.92% | 11.63% | 10.66% | 15.92% | 15.02% | 15.54% | |||||||||||||||
| Xyrem | 135.14M | 139.99M | 146.03M | 157.54M | 179.99M | 206.83M | 233.82M | 291.25M | |||||||||||||||
| Xyrem Growth | -24.92% | -32.31% | -37.54% | -45.91% | -49.76% | -54.63% | -58.96% | -59.01% | |||||||||||||||
| Sativex | 6.26M | 10.87M | 16.28M | 19.95M | 19.78M | 21.55M | 18.88M | 18.84M | |||||||||||||||
| Sativex Growth | -68.38% | -49.56% | -13.77% | 5.87% | 4.76% | 40.80% | -4.02% | -2.13% |